ASCO Genitourinary Cancers Symposium, 2022: A Focus on Prostate Cancer

PCE

English - March 17, 2022 13:00 - 27 minutes - 25.5 MB - ★★★★ - 6 ratings
Courses Education Science Life Sciences app education np education podcasts for credit app medicine pa education np medicine pa medicine ce podcasts app podcasts cme podcasts Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Gastric Cancer: New Strategies, New Therapies, New Hope, Part 2

Next Episode: Making Sense of the Expanding Options in Metastatic Colorectal Cancer Care: Part 1

In this podcast, Dr. Alicia Morgans discusses recent data presented at the 2022 ASCO GU Cancers Symposium, including trials evaluating the use of first-line PARP inhibitors in combination with abiraterone for mCRPC, continuation of enzalutamide after progression, and imaging modalities as predictive and prognostic biomarkers. This activity is available for CE/CME credit. Claim your credit at pce.is/ascogu.

Contributors:

Dr Morgans has disclosed that she has received funds for research support from Atellas, AstraZeneca, Bayer, Myovant, and Pfizer, and consulting fees from AAA, Astellas, AstraZeneca, Bayer, Blue Earth, Clovis, Dendreon, Janssen, Lantheus, Merck, Myovant, Novartis, Pfizer, Sanofi, and Telix.

Ms Martone has no relevant conflicts of interest to report.